Brain Metastasis in Triple-Negative Breast Cancer

Background. Breast cancer is an important cause of cancer-related death in women worldwide and represents the second most frequent cause of brain metastases after lung cancer. The aim of this study was to determine the characteristics and outcomes of triple-negative breast cancer (TNBC) patients wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Eduarda Bustamante, Fresia Casas, Renato Luque, Luis Piedra, Shamir Barros-Sevillano, Diego Chambergo-Michilot, J. Smith Torres-Roman, Alexis Narvaez-Rojas, Zaida Morante, Daniel Enriquez-Vera, Anshumi Desai, Cesar Razuri, Gabriel De la Cruz-Ku, Jhajaira Araujo
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:The Breast Journal
Online Access:http://dx.doi.org/10.1155/2024/8816102
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849414023427129344
author Eduarda Bustamante
Fresia Casas
Renato Luque
Luis Piedra
Shamir Barros-Sevillano
Diego Chambergo-Michilot
J. Smith Torres-Roman
Alexis Narvaez-Rojas
Zaida Morante
Daniel Enriquez-Vera
Anshumi Desai
Cesar Razuri
Gabriel De la Cruz-Ku
Jhajaira Araujo
author_facet Eduarda Bustamante
Fresia Casas
Renato Luque
Luis Piedra
Shamir Barros-Sevillano
Diego Chambergo-Michilot
J. Smith Torres-Roman
Alexis Narvaez-Rojas
Zaida Morante
Daniel Enriquez-Vera
Anshumi Desai
Cesar Razuri
Gabriel De la Cruz-Ku
Jhajaira Araujo
author_sort Eduarda Bustamante
collection DOAJ
description Background. Breast cancer is an important cause of cancer-related death in women worldwide and represents the second most frequent cause of brain metastases after lung cancer. The aim of this study was to determine the characteristics and outcomes of triple-negative breast cancer (TNBC) patients with brain metastasis (BM). Methods. We retrospectively reviewed a cohort of patients diagnosed with TNBC at the “Instituto Nacional de Enfermedades Neoplasicas” (period 2000–2014) to evaluate patients who developed BM. Survival rates were assessed by the Kaplan–Meier method, and prognostic factors were identified with the Cox regression analysis. Results. Of a total of 2007 TNBC patients, 193 (9.62%) developed BM. Of these, 169 stages I–III patients with a median age of 45 years (range:21–78) were included. The stage in this cohort was 4 (2.4%) clinical stage (CS) I, 23 (13.6%) with CS II and 142 (84.0%) with CS III. Most of these patients presented ECOG ≥2 (68.6%). The most common symptom was headache (74.0%), followed by nausea-vomiting (46.7%). Imaging showed that 80 patients (53.0%) had ≥1 metastatic brain lesion. Regarding the treatment of BM in this cohort, 132 patients (84.6%) received radiotherapy (RT), 2 (1.5%) surgery, and 6 (4.5%) surgery plus RT. The overall survival (OS) rate of BM was 59.8%, 37.3%, and 15.0% at 3, 6, and 12 months, respectively. A multivariate analysis showed RT to be the only factor with a positive impact on the OS of BM (hazard ratio (HR) = 0.48, 95% confidence interval (CI):0.30-0.77, and p=0.002), while ECOG ≥2 was associated with a worse OS (HR = 1.69, 95%CI:1.15–2.48, and p=0.007). Conclusion. Despite the poor prognosis of TNBC patients who develop BM, RT showed a benefit in OS rates, while ECOG ≥2 was the only prognostic factor associated with a worse OS. These results may be useful for multidisciplinary teams for treatment planning in patients with TNBC and BM.
format Article
id doaj-art-7115b2ef31904ccaa9c32a5ff04ee05f
institution Kabale University
issn 1524-4741
language English
publishDate 2024-01-01
publisher Wiley
record_format Article
series The Breast Journal
spelling doaj-art-7115b2ef31904ccaa9c32a5ff04ee05f2025-08-20T03:33:57ZengWileyThe Breast Journal1524-47412024-01-01202410.1155/2024/8816102Brain Metastasis in Triple-Negative Breast CancerEduarda Bustamante0Fresia Casas1Renato Luque2Luis Piedra3Shamir Barros-Sevillano4Diego Chambergo-Michilot5J. Smith Torres-Roman6Alexis Narvaez-Rojas7Zaida Morante8Daniel Enriquez-Vera9Anshumi Desai10Cesar Razuri11Gabriel De la Cruz-Ku12Jhajaira Araujo13Universidad Peruana de Ciencias AplicadasUniversidad Peruana Cayetano HerediaUniversidad Científica Del SurUniversidad Científica Del SurFacultad de Ciencias de la SaludUniversidad Científica Del SurSouth American Center for Education and Research Public HealthUniversity of Miami Miller School of MedicineInstituto Nacional de Enfermedades NeoplasicasInstituto Nacional de Enfermedades NeoplasicasUniversity of Miami Miller School of MedicineUniversidad Ricardo PalmaUniversidad Científica Del SurCentro de Investigación Básica y TraslacionalBackground. Breast cancer is an important cause of cancer-related death in women worldwide and represents the second most frequent cause of brain metastases after lung cancer. The aim of this study was to determine the characteristics and outcomes of triple-negative breast cancer (TNBC) patients with brain metastasis (BM). Methods. We retrospectively reviewed a cohort of patients diagnosed with TNBC at the “Instituto Nacional de Enfermedades Neoplasicas” (period 2000–2014) to evaluate patients who developed BM. Survival rates were assessed by the Kaplan–Meier method, and prognostic factors were identified with the Cox regression analysis. Results. Of a total of 2007 TNBC patients, 193 (9.62%) developed BM. Of these, 169 stages I–III patients with a median age of 45 years (range:21–78) were included. The stage in this cohort was 4 (2.4%) clinical stage (CS) I, 23 (13.6%) with CS II and 142 (84.0%) with CS III. Most of these patients presented ECOG ≥2 (68.6%). The most common symptom was headache (74.0%), followed by nausea-vomiting (46.7%). Imaging showed that 80 patients (53.0%) had ≥1 metastatic brain lesion. Regarding the treatment of BM in this cohort, 132 patients (84.6%) received radiotherapy (RT), 2 (1.5%) surgery, and 6 (4.5%) surgery plus RT. The overall survival (OS) rate of BM was 59.8%, 37.3%, and 15.0% at 3, 6, and 12 months, respectively. A multivariate analysis showed RT to be the only factor with a positive impact on the OS of BM (hazard ratio (HR) = 0.48, 95% confidence interval (CI):0.30-0.77, and p=0.002), while ECOG ≥2 was associated with a worse OS (HR = 1.69, 95%CI:1.15–2.48, and p=0.007). Conclusion. Despite the poor prognosis of TNBC patients who develop BM, RT showed a benefit in OS rates, while ECOG ≥2 was the only prognostic factor associated with a worse OS. These results may be useful for multidisciplinary teams for treatment planning in patients with TNBC and BM.http://dx.doi.org/10.1155/2024/8816102
spellingShingle Eduarda Bustamante
Fresia Casas
Renato Luque
Luis Piedra
Shamir Barros-Sevillano
Diego Chambergo-Michilot
J. Smith Torres-Roman
Alexis Narvaez-Rojas
Zaida Morante
Daniel Enriquez-Vera
Anshumi Desai
Cesar Razuri
Gabriel De la Cruz-Ku
Jhajaira Araujo
Brain Metastasis in Triple-Negative Breast Cancer
The Breast Journal
title Brain Metastasis in Triple-Negative Breast Cancer
title_full Brain Metastasis in Triple-Negative Breast Cancer
title_fullStr Brain Metastasis in Triple-Negative Breast Cancer
title_full_unstemmed Brain Metastasis in Triple-Negative Breast Cancer
title_short Brain Metastasis in Triple-Negative Breast Cancer
title_sort brain metastasis in triple negative breast cancer
url http://dx.doi.org/10.1155/2024/8816102
work_keys_str_mv AT eduardabustamante brainmetastasisintriplenegativebreastcancer
AT fresiacasas brainmetastasisintriplenegativebreastcancer
AT renatoluque brainmetastasisintriplenegativebreastcancer
AT luispiedra brainmetastasisintriplenegativebreastcancer
AT shamirbarrossevillano brainmetastasisintriplenegativebreastcancer
AT diegochambergomichilot brainmetastasisintriplenegativebreastcancer
AT jsmithtorresroman brainmetastasisintriplenegativebreastcancer
AT alexisnarvaezrojas brainmetastasisintriplenegativebreastcancer
AT zaidamorante brainmetastasisintriplenegativebreastcancer
AT danielenriquezvera brainmetastasisintriplenegativebreastcancer
AT anshumidesai brainmetastasisintriplenegativebreastcancer
AT cesarrazuri brainmetastasisintriplenegativebreastcancer
AT gabrieldelacruzku brainmetastasisintriplenegativebreastcancer
AT jhajairaaraujo brainmetastasisintriplenegativebreastcancer